Karen O’Hanlon Cohrt, Author at Labiotech.eu

About

Karen O’Hanlon Cohrt is a Science Writer and Editor with a PhD in biotechnology from Maynooth University, Ireland.

Articles by Karen O’Hanlon Cohrt

In Depth 4 Jan 2021

What Does the Next Decade Have in Store for European Biotech?

Just like that, another decade has gone by. It’s time to look at what the future will bring to the European biotech industry. European biotech has seen some huge breakthroughs and a few setbacks during the last 10 years. As we enter a new decade with great uncertainty due to the global Covid-19 pandemic, let’s […]

January 4, 2021 - 9 minutesmins - By Karen O’Hanlon Cohrt

In Depth 30 Dec 2020

A Look Back at the Past Decade of European Biotech

As we prepare to enter a new decade, we look back on the major milestones and blunders within European biotech over the last 10 years. Over the last decade, we have seen many biotech breakthroughs to come from Europe, including first-in-class therapies for cancer, the first approved in vivo gene therapy, as well as notable […]

December 30, 2020 - 15 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 7 May 2020

Lyme Disease Vaccine Gets Pfizer’s Backing in €284M Deal

The French biotech Valneva will collaborate with Pfizer to develop and commercialize Valneva’s phase II-stage Lyme disease vaccine candidate. The deal they signed is expected to help compensate for the impact of the Covid-19 pandemic on Valneva’s financial outlook for 2020. The latest alliance will pool Valneva’s vaccine R&D expertise with Pfizer’s vast drug development […]

May 7, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 27 Apr 2020

Series A Round Boosts Swedish Synthetic Biology Player by €6.4M

The Swedish synthetic biology company EnginZyme has raised a Series A funding round to the tune of €6.4M to develop its cell-free synbio technology for the sustainable production of plastic, rubber, and other synthetic materials. The latest investment, which was led by French venture fund Sofinnova Partners, brings EnginZyme’s total funding to more than €10M […]

April 27, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 21 Apr 2020

Idorsia’s Drug Improves Sleep in First Phase III Trial for Insomnia

The Swiss pharmaceutical company Idorsia has announced that its drug candidate daridorexant significantly improved sleep onset, sleep quality, and daytime functioning of insomnia patients in a pivotal phase III trial. The trial recruited 930 adult patients with insomnia. The company used a technique called polysomnography to measure the time taken to fall asleep and sleep […]

April 21, 2020 - 3 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 31 Mar 2020

Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial

The French pharmaceutical company Ipsen has restarted the dosing of its treatment for a rare bone disease in a phase III trial after obtaining questionable interim results. At the same time, the company has terminated a phase II trial of the same drug in pediatric patients with a different bone disorder following a partial clinical […]

March 31, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

Best in Biotech 20 Jan 2020

How Much Salary Can You Expect in a Biotech Job?

If you’re thinking of taking a job in biotech, you’re probably wondering how much you’ll be paid. Here’s what you can expect depending on how high in the ladder your new position is. Salary is undoubtedly an important factor when searching for a new job position, so it’s important to know what you can expect. […]

January 20, 2020 - 7 minutesmins - By Karen O’Hanlon Cohrt

In Depth 25 Mar 2019

Where Does Brexit Leave European Biotech?

In the next couple of months, the UK will officially exit the EU, in a move that is popularly known as Brexit. With this date fast approaching, companies, organizations and individuals all over the world have speculated about how Brexit might impact them. According to the UK Prime Minister, Theresa May, at the launch of […]

March 25, 2019 - 9 minutesmins - By Karen O’Hanlon Cohrt

Best in Biotech 30 Apr 2018

The 5 Best-Selling European Drugs of 2017

Biologicals have completely changed the way we treat diseases, and their growth has exploded in the last two decades. Not surprisingly, they took a whopping 7 out of 15 spots on the list of 2017’s best selling drugs globally. We were of course keen to find out how European-derived drugs faired out in this list. […]

April 30, 2018 - 7 minutesmins - By Karen O’Hanlon Cohrt

Best in Biotech 20 Feb 2018

Money, Money, Money! Europe’s Best-Funded Biotechs in 2018

Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on the brain, we thought it would be a good time to do a roundup of Europe’s best-funded private biotechs. With over €400M raised to date, […]

February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us